...

Poor target selection is the leading reason for clinical trial failure, with approximately 50% of trials falling short due to lack of efficacy. Most efficacy related failures are attributable to poor disease-target linkage. To navigate this, drug discovery teams need to have an extensive understanding of the underlying disease biology, target safety profile, availability of biomarkers, and more.

Balancing these considerations is far from simple. The exponential growth of biomedical data makes target prioritization and selection deeply complex. Modern drug discovery scientists urgently need effective tools that help them manage the data overload, reduce bias and separate signal from noise.

Target Identification and Prioritization introduction image

Build foundational understanding of disease biology to design targeted therapies

  • Explore molecular and cellular processes associated with the disease to establish the critical points where interventions can be targeted.
  •  
     
  • Analyze pathways and signalling networks to focus on targets that play a pathogenic role in the disease process.
Build foundational understanding of disease biology to design targeted therapies

Identify & prioritize novel and validated targets to focus resources

  • Causaly reads the scientific data within seconds to identify a list of potential targets. Deeply explore the supporting evidence for each target-disease association, including directional effects and contradictory findings.
  •  
     
  • Easily identify novel targets by focusing on emerging findings, considering targets with little validation, or exploring targets yet to be directly associated with the disease of interest.
  •  
     
  • With multiple criteria for prioritization, rapidly filter for validated targets in Causaly by assessing the strength of disease-target linkage, genetic evidence, validation in animal models, human relevance, druggability, and more. Tailor your selection process to match your specific needs.
Identify & prioritize novel and validated targets to focus resources

Stay up to date with the latest and most comprehensive data

  • Stay on top of your research area with customizable alerts that notify you the moment new evidence appears.
  •  
     
  • Have confidence that you are not missing any relevant data with our comprehensive target ontology. Dive deep into specific target classes such as enzymes, receptors, membrane transporters to uncover new possibilities to focus your discovery programs.
Stay up to date with the latest and most comprehensive data

Build foundational understanding of disease biology to design targeted therapies

  • Explore molecular and cellular processes associated with the disease to establish the critical points where interventions can be targeted.
  •  
     
  • Analyze pathways and signalling networks to focus on targets that play a pathogenic role in the disease process.
Build foundational understanding of disease biology to design targeted therapies

Accelerate Your Discovery Programs

Gain up to 90% in research productivity and focus resources on validated targets or explore more novel directions.

Terminate Non-Promising Projects Early

Establish the strength of the underlying disease biology, identify safety red-flags, and look for competitive signals at the inception of discovery projects.

Make More and Bigger Scientific Bets

Increase the number of innovative bets through open-ended, exploratory questions that allow you to consider adjacencies and increase chances of novel discoveries – without running a single experiment.

What our clients say

"What I find really helpful is the ability to visualize the research in different ways - it is great to get a quick overview of how much knowledge is available."
Principal Scientist
Top 50 Pharma
"An advantage of Causaly is where I am investigating the mechanism of action for a gene of interest - I can use the platform to understand the cellular and molecular function of the gene in the disease and it will point me towards best publications to review."
Senior Scientist
Top 50 Pharma
"I love how Causaly's functionality allows me to generate hypotheses and gain inspiration whilst doing research, e.g. while exploring which tissues or cells are affected."
Principal Scientist
Top 50 Pharma
"What I find really helpful is the ability to visualize the research in different ways - it is great to get a quick overview of how much knowledge is available."
Principal Scientist
Top 50 Pharma
"An advantage of Causaly is where I am investigating the mechanism of action for a gene of interest - I can use the platform to understand the cellular and molecular function of the gene in the disease and it will point me towards best publications to review."
Senior Scientist
Top 50 Pharma
"I love how Causaly's functionality allows me to generate hypotheses and gain inspiration whilst doing research, e.g. while exploring which tissues or cells are affected."
Principal Scientist
Top 50 Pharma
"What I find really helpful is the ability to visualize the research in different ways - it is great to get a quick overview of how much knowledge is available."
Principal Scientist
Top 50 Pharma

Target Selection Resources

Identifying Targets in Gastrointestinal Stromal Tumors Featured Image
Andrew Taylor • July 12, 2023

Identifying Targets in Gastrointestinal Stromal Tumors

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

HLA-DQA1 as a Target for Chronic Obstructive Pulmonary Disease (COPD) Featured Image
Andrew Taylor • June 29, 2023

HLA-DQA1 as a Target for Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening respiratory condition caused by airway obstruction. It ranks among the top global causes of death, with over 200 million cases and 3 million deaths reported in 2019.

Perforin (PRF1) as An Emerging Target for Type 1 Diabetes Featured Image
Andrew Taylor • June 27, 2023

Perforin (PRF1) as An Emerging Target for Type 1 Diabetes

Diabetes is a complex metabolic disorder which disrupts the balance of blood sugar in the body, affecting over 400 million people worldwide.¹ According to the World Health Organization (WHO), around 1.5 million deaths each year are directly attributable to diabetes, highlighting the critical need for research into this disease.

Target Identification and Prioritization: A Kidney Cancer Use Case Featured Image
Andrew Taylor • June 15, 2023

Target Identification and Prioritization: A Kidney Cancer Use Case

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.

Strong growth in autoimmune drug target discovery in 2022 Featured Image
Andrew Taylor • May 22, 2023

Strong growth in autoimmune drug target discovery in 2022

Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.

Momentum builds in lupus R&D Featured Image
Andrew Taylor • May 5, 2023

Momentum builds in lupus R&D

Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness.

Knowledge discovery reimagined: finding new hypotheses with Causaly Cloud Featured Image
Maria Tella • June 30, 2022

Knowledge discovery reimagined: finding new hypotheses with Causaly Cloud

Being able to stay up to date with scientific data and efficiently extracting insights is critical to drug R&D – but currently it is a manual, time-consuming process

Watch Causaly’s panel discussion from Discovery Europe Featured Image
Maria Tella • June 30, 2022

Watch Causaly’s panel discussion from Discovery Europe

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe.